biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > $5.25 million

<< Previous

Bullboard Posts

Next >>

Comment by Boomskidon Feb 28, 2023 9:01am

135 Views

Post# 35309155

RE:$5.25 million

Hah, poof, thank you for recognizing the LSD deal I have proposed for years. I proposed selling the entire rights to LSDs for $30 million to $50 million, all in, no royalties, possibly enough to get xB3-001 through phase 1b/2.

My guess is that Bioasis would have to include all rights to xB3-004 to get half that much now ($15 million to $25 million). Chiesi stuck it to Bioasis during hard times with the original deal of $3 million up front and only $138 million in milestone payments for 4 LSDs.
.
I'm not sure such a deal would fit Bioasis management and BoD's personal objectives but it could allow Bioasis to stand and fight another day.

jd

<< Previous

Bullboard Posts

Next >>

The top TSX healthcare stocks under $1